### **Company Overview** Natural Capsules Limited (NCL), incorporated in 1993 and headquartered in Bengaluru, India, is a leading manufacturer of hard capsule shells and a pioneer in the Indian pharmaceutical industry for introducing vegetarian (HPMC) capsules. The company is the **second-largest Indian producer of gelatin capsules**, operating manufacturing facilities in **Bengaluru and Puducherry**. Listed on the BSE since 1994, NCL serves over **294 customers** globally across **28 countries** and employs **619 team members** as of FY25. The company has evolved into a **multi-vertical pharmaceutical player**, diversifying from capsule manufacturing into the **Active Pharmaceutical Ingredient (API)** space through its wholly-owned subsidiary, **Natural Biogenex Private Limited (NBPL)**, established in 2020. This strategic expansion positions NCL as India’s **only backward-integrated manufacturer of steroidal APIs**, strengthening domestic self-reliance in critical pharmaceuticals. --- ### **Strategic Priorities & Growth Vision** NCL’s long-term vision centers on: - Becoming the **market leader in capsules** globally. - Establishing dominance in the **domestic steroidal API market**. - Expanding its **global footprint** with a focus on regulated markets (US, EU, Canada, Brazil, South Africa). - Reducing **margin volatility** by migrating toward high-value, regulated export markets. To achieve these goals, the company is executing a robust capital expenditure (CAPEX) plan focused on **capacity expansion, technological advancement, and backward integration**. Investments have reached approximately **₹175 crores in the API segment**, supported by a **strategic equity investment of ₹75 crores from Somerset Indus Capital Partners** in NBPL. --- ### **Core Business Segments** #### **1. Capsule Manufacturing** - **Product Portfolio**: Hard gelatin capsules, vegetarian HPMC capsules, and specialized variants (fast-release, shiny, sweet, SLS-free, preservative-free, TSE-free). - **Capacity**: **19.5 billion capsules per annum (BCPA)** in FY25, up from 7 billion in FY20 — an **~180% expansion**. - **Technology**: Collaborated with **DBDS Robotics Private Limited** to co-develop next-generation capsule machines — the **fastest available**, capable of up to **5 million capsules per day per line**, consuming **40% less power** and reducing labor and rejection rates (from 8% to 3%). - **Revenue & Margins**: - Capsule sales expected to contribute **₹235–240 crores** from HPMC capacity. - EBITDA margins: **16–18%**, supported by product mix optimization and falling gelatin prices. #### **2. HPMC Capsule Business – Key Growth Driver** - NCL launched its **first HPMC line in Q4 FY24**, overcoming initial delays in customer approvals. - **Commercial traction is now accelerating** due to a favorable U.S. anti-dumping duty structure: **88% on Chinese HPMC capsules vs. 14% on Indian capsules**, granting NCL a competitive cost advantage. - HPMC revenue is projected to grow from **₹9 crores (FY25) to ₹27 crores in FY26**. - The company plans to **add two more HPMC lines** and may convert gelatin lines to HPMC if demand persists. - Offers **10–15% better profitability** than gelatin variants, driving a strategic shift in product mix. --- ### **API Manufacturing – Strategic Diversification** #### **Subsidiary: Natural Biogenex Private Limited (NBPL)** - **Facility**: A greenfield, **zero-liquid-discharge plant** in **Tumkur, Karnataka**, spread across 5 acres, designed to meet **WHO GMP, USFDA, and EU GMP** standards. - **Technology**: Uses **in-house patented fermentation and synthesis processes** — a **first-of-its-kind integrated model in India** — to produce steroidal APIs from key starting materials (KSMs). - **Products**: - **Hydrocortisone, Prednisolone, Betamethasone, Dexamethasone**, and their derivatives. - **Only Indian manufacturer of Dexamethasone and Betamethasone**; one of two for Prednisolone. - **PLI Scheme Support**: Three products (**Dexamethasone, Betamethasone, Prednisolone**) approved under India's **Production Linked Incentive (PLI) Scheme** for bulk drugs, offering up to **20% incentives on incremental sales (FY26–FY28)**. - **Export Potential**: Aims to achieve **USFDA and EU GMP certification within 2–3 years**, enabling entry into high-margin regulated markets. #### **Commercialization & Milestones** - **Commercial production began in March 2025**, though scale-up was delayed due to pending environmental approvals. - **Trial batches** of Dexamethasone and Prednisolone supplied to **>89 pharmaceutical partners**; stability data and dossiers shared with **23+ companies**. - **API revenue**: Expected **₹65 crores** in current year, with **target of ₹100 crores in FY26**. - **EBITDA Margin Goal**: Near-term margins of **7–10%** (domestic), scaling to **>20%** with exports and scale. - **Cash breakeven** expected by **FY26**; **WHO GMP audit scheduled for H1 FY26**. --- ### **R&D & Innovation** - **R&D Center Established**: August 2018, focused on microbial fermentation for steroidal API synthesis. - **Patents Filed**: - Innovative **9-OH-AD manufacturing process** (2019, 2024). - **Bioconversion technology** (Q4 FY25) — strengthens IP portfolio. - **Key Milestones**: - Lab-scale production of **Hydrocortisone from 9OHAD achieved (July 2019)**. - Second fermentation process for **Prednisolone initiated**. - **DSIR-Recognized Facility** with **32 R&D professionals**; **4 granted patents**, 4 under review/filing. - **Incentives**: ESOPs for senior R&D staff to align innovation with performance. --- ### **Market Position & Exports** - **Global Reach**: Exports to **28 countries across Africa, Asia, CIS, Middle East, South America, and North America**. - **Key Markets**: Nigeria, Kenya, South Africa, UAE, Iran, Brazil, USA, Canada, Mexico. - **Export Revenue**: - **31.23% of FY25 revenue** from exports (down from **36.7% in FY24** due to strategic repositioning). - Revenue concentration: **Africa (45.6%)**, Asia (23.2%), North America (21.5%). - **Domestic Strategy**: Shifted from volatile "Rest of World" (ROW) markets to **large-volume Indian pharma companies** — targeting top 40–50 domestic players. --- ### **Competitive Advantages** - **Cost Leadership**: **60–70% lower cost** than Chinese competitors in HPMC capsule exports to the US. - **Regulatory Edge**: Favorable U.S. trade policy and strong CAPEX in compliance infrastructure. - **Backward Integration**: Eliminates dependency on Chinese intermediates — a key selling point under the **"China+1" sourcing trend**. - **Innovation & IP**: Proprietary bioconversion technology and process control systems enhance defensibility. - **Sustainability**: Zero-liquid-discharge API plant and **10.36 MW captive power project**, reducing energy costs by **₹2.5–3 crores annually**. --- ### **Challenges & Risk Mitigation** - **API Pricing Pressure**: **12–15% global price decline** due to Chinese overcapacity. - **Mitigation**: Advocacy for **minimum import price (MIP)** under PLI scheme; focus on long-term contracts. - **Scale-up Delays**: Fermentation yield and regulatory approvals initially slowed API ramp-up. - **Mitigation**: Hired **external consultants**, improved process controls, and filed new patents. - **Gelatin Market Volatility**: NCL is **diversifying toward HPMC** to hedge margin risk.